thiophenes has been researched along with Multiple Myeloma in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.55) | 18.2507 |
| 2000's | 1 (4.55) | 29.6817 |
| 2010's | 11 (50.00) | 24.3611 |
| 2020's | 9 (40.91) | 2.80 |
| Authors | Studies |
|---|---|
| Boutin, R; Guan, TL; Lacbay, CM; Lee, HF; Matralis, AN; Park, J; Sebag, M; Tsantrizos, YS; Waller, DD | 1 |
| Jakubowiak, AJ; Johnson, D; Nakamura, Y; Park, JH; Rosebeck, S; Stefka, AT | 1 |
| Cao, B; He, Y; Jiang, S; Mao, X; Moran, MF; Tong, J; Wang, S; Xu, Y; Yang, Y; Zeng, Y; Zhang, Z | 1 |
| Chim, CS; Wong, KY | 1 |
| Hanamura, I; Hosokawa, Y; Hyodo, T; Kanasugi, J; Karnan, S; Konishi, H; Lam, VQ; Mizuno, S; Ota, A; Rahman, ML; Takami, A; Tsuzuki, S; Wahiduzzaman, M | 1 |
| Amiot, M; Bellanger, C; Descamps, G; Gomez-Bougie, P; Kervoëlen, C; Maiga, S; Maillet, L; Moreau, P; Pellat-Deceunynck, C; Seiller, C; Touzeau, C | 1 |
| Algarín, EM; Campos-Laborie, FJ; De Las Rivas, J; Díaz-Tejedor, A; Garayoa, M; García-Sanz, R; González-Méndez, L; Gutiérrez, NC; Martín-Sánchez, M; Mogollón, P; Ocio, EM; Paíno, T; Quwaider, D; San-Segundo, L; Vuelta, E | 1 |
| Brdon, J; Burger, R; Gramatzki, M; Otte, A; Peipp, M | 1 |
| Barbosa-Dantas, RSS; Colleoni, GWB; de Oliveira, MB; Eugenio, AIP; Sanson, LFG | 1 |
| Algarín, EM; Banquet, S; Corchete, LA; Derreal, A; Díaz-Tejedor, A; Garayoa, M; González-Méndez, L; Gutiérrez, NC; Halilovic, E; Hernández-García, S; Kloos, I; Kraus-Berthier, L; Maacke, H; Martín-Sánchez, M; Mateos, MV; Mogollón, P; Ocio, EM; Paíno, T; San-Segundo, L; Schoumacher, M | 1 |
| Bargou, RC; Giner, T; Maier, E; Rauert-Wunderlich, H; Siegmund, D; Stühmer, T; Wajant, H | 1 |
| Brigandi, RA; Chen, C; Gauvin, J; Harrison, SJ; Kumar, R; Morris, SR; Opalinska, JB; Smith, DA; Spencer, A; Yoon, SS | 1 |
| Leleu, X | 1 |
| Aktan, G; Allred, AJ; Becerra, CR; Cornfeld, M; Ferron-Brady, G; Gauvin, J; Ibrahim, N; Motwani, M; Orford, K; Papadopoulos, KP; Patnaik, A; Rasco, DW; Tolcher, AW | 1 |
| Abe, M; Amachi, R; Hanson, DJ; Harada, T; Hiasa, M; Horikawa, K; Itoh, K; Matsumoto, T; Miki, H; Nakamura, S; Oda, A; Teramachi, J; Tsuji, D | 1 |
| Aubrey, BJ; Balint, B; Blasko, G; Brennan, MS; Bruno, A; Cauquil, N; Chang, C; Chanrion, M; Chen, I; Colland, F; Csekei, M; Davidson, J; Dokurno, P; Galbraith, LC; Geneste, O; Girard, AM; Gong, JN; Graham, C; Gravé, F; Guasconi, G; Guigal-Stephan, N; Herold, MJ; Hickman, JA; Huang, DC; Kelly, GL; Kotschy, A; Le Toumelin-Braizat, G; Lessene, G; Lockhart, B; Lysiak-Auvity, G; Maragno, AL; Matassova, N; Melchiore, F; Moujalled, DM; Murray, J; Ondi, L; Paczal, A; Pedder, C; Pomilio, G; Proszenyak, A; Radics, G; Riffkin, CD; Roberts, AW; Robertson, A; Segal, D; Sipos, S; Smith, J; Strasser, A; Studeny, A; Surgenor, A; Szabo, ZB; Szlavik, Z; Wei, AH | 1 |
| Bouley, DM; Denko, NC; Koong, AC; Lust, S; Niwa, M; Offner, F; Olson, M; Papandreou, I; Solow-Cordero, DE; Tam, A; Van Melckebeke, H | 1 |
| Almenara, JA; Bodie, WW; Chen, S; Dai, Y; Dent, P; Felthousen, J; Grant, S; Kramer, LB; Pei, XY; Takabatake, Y; Youssefian, LE | 1 |
| Asai, T; Comenzo, RL; Friedman, H; Jhanwar, SC; Landau, HJ; McNeely, SC; Nair, JS; Nimer, SD; Schwartz, GK | 1 |
| Altun, M; Anderson, KC; Carrasco, R; Chauhan, D; Fulcinniti, M; Hideshima, T; Kessler, BM; Kingsbury, WD; Kodrasov, MP; Kumar, KG; Leach, CA; McDermott, JL; Minvielle, S; Munshi, N; Nicholson, B; Orlowski, R; Richardson, P; Shah, PK; Tian, Z; Weinstock, J; Zhou, B | 1 |
| Antcliff, J; Croucher, PI; Hargreaves, PG; Lawry, J; Murphy, G; Russell, RG; Wang, F | 1 |
| Briehl, MM; Dorr, RT; Dvorakova, K; Payne, CM; Tome, ME; Waltmire, CN | 1 |
2 trial(s) available for thiophenes and Multiple Myeloma
| Article | Year |
|---|---|
The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Female; Hematologic Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Patient Safety; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Thiophenes; Time Factors; Young Adult | 2014 |
Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Dose-Response Relationship, Drug; Early Termination of Clinical Trials; Female; Humans; Male; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Middle Aged; Multiple Myeloma; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyridones; Pyrimidinones; Thiophenes; Tumor Burden | 2015 |
20 other study(ies) available for thiophenes and Multiple Myeloma
| Article | Year |
|---|---|
Synthesis and Evaluation of Structurally Diverse C-2-Substituted Thienopyrimidine-Based Inhibitors of the Human Geranylgeranyl Pyrophosphate Synthase.
Topics: Animals; Antineoplastic Agents; Bone Marrow Cells; Enzyme Inhibitors; Female; Fungal Proteins; Geranylgeranyl-Diphosphate Geranylgeranyltransferase; Humans; Liver; Male; Mice, Inbred C57BL; Molecular Structure; Multiple Myeloma; Protein Binding; Pyrimidines; Rats; Saccharomyces cerevisiae; Structure-Activity Relationship; Thiophenes | 2022 |
Potent anti-myeloma activity of the TOPK inhibitor OTS514 in pre-clinical models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Drug Synergism; Female; Humans; Lenalidomide; Leukocytes, Mononuclear; Mice; Mitogen-Activated Protein Kinase Kinases; Multiple Myeloma; Primary Cell Culture; Protein Kinase Inhibitors; Quinolones; Thiophenes; Xenograft Model Antitumor Assays | 2020 |
The deubiquitinase USP7 stabilizes Maf proteins to promote myeloma cell survival.
Topics: Apoptosis; Carcinogenesis; Cell Proliferation; Cell Survival; Female; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Maf Transcription Factors, Large; MafB Transcription Factor; Male; Multiple Myeloma; Polyubiquitin; Progression-Free Survival; Proteolysis; Proto-Oncogene Proteins c-maf; Thiophenes; Ubiquitin-Specific Peptidase 7; Ubiquitination | 2020 |
Venetoclax, bortezomib and S63845, an MCL1 inhibitor, in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 14; Drug Resistance, Neoplasm; Drug Synergism; Humans; Inhibitory Concentration 50; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Sulfonamides; Thiophenes; Translocation, Genetic | 2020 |
Biallelic loss of FAM46C triggers tumor growth with concomitant activation of Akt signaling in multiple myeloma cells.
Topics: Animals; Antineoplastic Agents; Bortezomib; Carcinogenesis; Cell Cycle; Cell Line, Tumor; Cell Survival; Female; Gene Expression Regulation, Neoplastic; Gene Knockout Techniques; Humans; Mice; Mice, SCID; Multiple Myeloma; Nucleotidyltransferases; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrazoles; Signal Transduction; Thiophenes | 2020 |
Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Recurrence, Local; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Thiophenes | 2020 |
Stroma-Mediated Resistance to S63845 and Venetoclax through MCL-1 and BCL-2 Expression Changes Induced by miR-193b-3p and miR-21-5p Dysregulation in Multiple Myeloma.
Topics: Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Sulfonamides; Thiophenes | 2021 |
Dual intracellular targeting by ruxolitinib and the Mcl-1 inhibitor S63845 in interleukin-6-dependent myeloma cells blocks
Topics: Apoptosis; Cell Line, Tumor; Humans; Interleukin-6; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein; Nitriles; Proto-Oncogene Proteins c-bcl-2; Pyrazoles; Pyrimidines; Thiophenes | 2021 |
Stew in its Own Juice: Protein Homeostasis Machinery Inhibition Reduces Cell Viability in Multiple Myeloma Cell Lines.
Topics: Apoptosis; Autophagy; Benzamides; Bortezomib; Cell Survival; Drug Synergism; HSP70 Heat-Shock Proteins; Humans; Multiple Myeloma; Proteasome Inhibitors; Proteostasis; Pyrimidines; Sulfonamides; Thiophenes; Tumor Cells, Cultured; Unfolded Protein Response | 2019 |
Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma.
Topics: Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Humans; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Sulfonamides; Thiophenes | 2020 |
The IKK inhibitor Bay 11-7082 induces cell death independent from inhibition of activation of NFκB transcription factors.
Topics: Amides; Apoptosis; Blotting, Western; Cell Line; Cell Survival; Cyclopentanes; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; I-kappa B Kinase; Microscopy, Fluorescence; Multiple Myeloma; NF-kappa B; Nitriles; Pyrimidines; RNA, Small Interfering; Signal Transduction; Sulfones; Thiophenes | 2013 |
A key to the quest?
Topics: Female; Humans; Male; Multiple Myeloma; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Thiophenes | 2014 |
Effective impairment of myeloma cells and their progenitors by blockade of monocarboxylate transportation.
Topics: Cell Death; Cell Line, Tumor; Coumaric Acids; Gene Knockdown Techniques; Humans; Hydrogen-Ion Concentration; Metformin; Molecular Targeted Therapy; Monocarboxylic Acid Transporters; Multiple Myeloma; Muscle Proteins; Neoplastic Stem Cells; Symporters; Thiophenes; Uracil | 2015 |
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Cell Line, Tumor; Female; Humans; Leukemia; Lymphoma; Male; Mice; Models, Biological; Models, Molecular; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms; Pyrimidines; Thiophenes; Xenograft Model Antitumor Assays | 2016 |
Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cells, Cultured; Cytotoxins; Dose-Response Relationship, Drug; Endoribonucleases; Humans; Mice; Models, Biological; Multiple Myeloma; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazines; Substrate Specificity; Sulfonamides; Thiophenes; Xenograft Model Antitumor Assays | 2011 |
Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2.
Topics: Apoptosis; Benzimidazoles; Cell Line, Tumor; Checkpoint Kinase 1; DNA Damage; G1 Phase; Humans; Interleukin-6; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Multiple Myeloma; Protein Kinase Inhibitors; Protein Kinases; Resting Phase, Cell Cycle; Syndecan-1; Thiophenes; Urea | 2011 |
The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Checkpoint Kinase 1; Drug Synergism; Humans; Micronuclei, Chromosome-Defective; Multiple Myeloma; Mutation; Protein Kinase Inhibitors; Protein Kinases; Signal Transduction; Thiophenes; Tumor Suppressor Protein p53; Urea | 2012 |
A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Dexamethasone; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Lenalidomide; Mice; Mice, SCID; Molecular Sequence Data; Multiple Myeloma; Neovascularization, Pathologic; Protease Inhibitors; Proto-Oncogene Proteins c-mdm2; Pyrazines; Random Allocation; Thalidomide; Thiophenes; Ubiquitin Thiolesterase; Ubiquitin-Specific Peptidase 7; Xenograft Model Antitumor Assays | 2012 |
Human myeloma cells shed the interleukin-6 receptor: inhibition by tissue inhibitor of metalloproteinase-3 and a hydroxamate-based metalloproteinase inhibitor.
Topics: Bone Marrow Cells; Dose-Response Relationship, Drug; Humans; Multiple Myeloma; Phenylalanine; Protease Inhibitors; Receptors, Interleukin-6; Tetradecanoylphorbol Acetate; Thiophenes; Tissue Inhibitor of Metalloproteinase-3; Tumor Cells, Cultured | 1998 |
Induction of mitochondrial changes in myeloma cells by imexon.
Topics: Acetone; Acetylcysteine; Antineoplastic Agents; Antioxidants; Apoptosis; Cytochrome c Group; DNA Damage; DNA, Mitochondrial; Electron Transport Complex II; Flow Cytometry; Hexanones; Humans; Leukemia, Promyelocytic, Acute; Lymphocytes; Membrane Potentials; Microscopy, Electron; Mitochondria; Multienzyme Complexes; Multiple Myeloma; Oxidative Stress; Oxidoreductases; Polymerase Chain Reaction; Reactive Oxygen Species; Succinate Dehydrogenase; Thiophenes; Tumor Cells, Cultured | 2001 |